{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:53:59Z","timestamp":1782996839749,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":2825,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1093\/annonc\/mdr275","type":"journal-article","created":{"date-parts":[[2011,6,9]],"date-time":"2011-06-09T12:00:30Z","timestamp":1307620830000},"page":"714-721","source":"Crossref","is-referenced-by-count":57,"title":["Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?"],"prefix":"10.1016","volume":"23","author":[{"given":"R.","family":"Sabatier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Eymard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Deville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Narbonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Boher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Marcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Brunelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Viens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bladou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdr275_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10456-009-9160-6","article-title":"Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?","volume":"13","author":"Gotink","year":"2010","journal-title":"Angiogenesis"},{"key":"10.1093\/annonc\/mdr275_bb0015","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alpha in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr275_bb0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr275_bb0025","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdr275_bb0030","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1210\/jc.2007-0586","article-title":"A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake","volume":"92","author":"Mannavola","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mdr275_bb0035","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/thy.2006.0308","article-title":"Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity","volume":"17","author":"Wong","year":"2007","journal-title":"Thyroid"},{"key":"10.1093\/annonc\/mdr275_bb0040","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-145-9-200611070-00008","article-title":"Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumours","volume":"145","author":"Desai","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1093\/annonc\/mdr275_bb0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jnci\/djk008","article-title":"Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"99","author":"Rini","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdr275_bb0050","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/sj.bjc.6604497","article-title":"The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation","volume":"99","author":"Wolter","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdr275_bb0055","first-page":"617","article-title":"Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I\/II study","volume":"23","author":"Hercbergs","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdr275_bb0060","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/cncr.20881","article-title":"Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma","volume":"103","author":"Cristofanilli","year":"2005","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdr275_bb0065","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1001\/archotol.132.10.1041","article-title":"Association between development of hypothyroidism and improved survival in patients with head and neck cancer","volume":"132","author":"Nelson","year":"2006","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1093\/annonc\/mdr275_bb0070","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of survival by tumour response","volume":"1","author":"Anderson","year":"1983","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr275_bb0075","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10985-008-9099-8","article-title":"Dynamic predicting by landmarking as an alternative for multi-state modeling: an application to acute lymphoid leukaemia data","volume":"14","author":"Van Houwelingen","year":"2008","journal-title":"Lifetime Data Anal"},{"key":"10.1093\/annonc\/mdr275_bb0080","doi-asserted-by":"crossref","first-page":"9067","DOI":"10.1200\/JCO.2004.01.0454","article-title":"Reporting recommendations for tumour marker prognostic studies","volume":"23","author":"McShane","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr275_bb0085","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr275_bb0090","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alpha in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr275_bb0095","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jama.291.2.228","article-title":"Subclinical thyroid disease, scientific review and guidelines for diagnosis and management","volume":"291","author":"Surks","year":"2004","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdr275_bb0100","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.21146","article-title":"The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification","volume":"43","author":"Mandac","year":"2006","journal-title":"Hepatology"},{"key":"10.1093\/annonc\/mdr275_bb0105","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJM198806163182401","article-title":"Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells","volume":"318","author":"Atkins","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr275_bb0110","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.1993.11.7.1376","article-title":"Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment","volume":"11","author":"Weijl","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr275_bb0115","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/jnci\/djm006","article-title":"Re: hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"99","author":"Feldman","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdr275_bb0120","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1089\/thy.2005.15.24","article-title":"Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society","volume":"15","author":"Gharib","year":"2005","journal-title":"Thyroid"},{"key":"10.1093\/annonc\/mdr275_bb0125","doi-asserted-by":"crossref","first-page":"H560","DOI":"10.1152\/ajpheart.00133.2005","article-title":"VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature","volume":"290","author":"Kamba","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1093\/annonc\/mdr275_bb0130","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1089\/thy.2007.0349","article-title":"Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies","volume":"18","author":"Alexandrescu","year":"2008","journal-title":"Thyroid"},{"key":"10.1093\/annonc\/mdr275_bb0135","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/jnci\/djm008","article-title":"Re: hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"99","author":"Garfield","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdr275_bb0140","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1586\/17446651.1.6.753","article-title":"Cell-surface receptor for thyroid hormone and tumour cell proliferation","volume":"1","author":"Davis","year":"2006","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"Suppl","key":"10.1093\/annonc\/mdr275_bb0145","first-page":"280s","article-title":"Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients with advanced renal cell carcinoma","volume":"26","author":"Wolter","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr275_bb0150","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cncr.25422","article-title":"Hypothyroidism in patients with renal cell carcinoma: blessing or curse?","volume":"117","author":"Schmidinger","year":"2011","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdr275_bb0155","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1200\/JCO.2008.18.8680","article-title":"Documentation of thyroid function in clinical studies with sunitinib; why does it matter?","volume":"26","author":"Garfield","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr275_bb0160","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ncponc0998","article-title":"Unanswered questions regarding the management of sunitinib-induced hypothyroidism","volume":"4","author":"Garfield","year":"2007","journal-title":"Nat Clin Pract Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419344370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419344370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/3\/714\/605744\/mdr275.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T09:06:06Z","timestamp":1624439166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419344370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0923753419344370"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdr275","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}